



08-08-07

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1617  
Ifu

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/561, 656	
	Filing Date	November 17, 2006	
	First Named Inventor	Jong Joseph Kim	
	Art Unit		
	Examiner Name	To Be Determined	
Total Number of Pages in This Submission		Attorney Docket Number	133121.00201

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms SB/08a and SB/08b (9 pp.); ( 114) References Cited, (57) References Enclosed.
<b>Remarks</b> <b>EXPRESS MAIL LABEL NO: EM 028 283 267 US</b> <b>DATE OF DEPOSIT: August 6, 2007</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Pepper Hamilton LLP		
Signature			
Printed Name	Mark DeLuca		
Date	8/7/07	Reg. No.	33,229

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



DOCKET NO.: 133121.00201

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Jong Joseph Kim**

Application No.: **10/561,656**

Group Art Unit: **1617**

Filing Date: **November 17, 2006**

Examiner: **To Be Determined**

For: **ANTIVIRAL COMPOSITIONS AND METHODS OF USING THE SAME**

**EXPRESS MAIL LABEL NO.: EM 028 283 267 US**  
**DATE OF DEPOSIT: August 6, 2007**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
  - ☐ the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below);
  - or**
  - ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
  - ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see “Statement,” and “Fees” below).
- ☒ Copies of the references listed on the attached PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449 are enclosed.

**EXCEPT THAT:**

- ☒ In view of the voluminous nature of reference **Citation No. 114**, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

**Statement under 37 C.F.R. § 1.97(e)**

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.


**Fees**

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$\_\_\_\_\_. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-0436.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).


Respectfully submitted,



Mark DeLuca  
Registration No. 33,229

Dated: 8/7/07

PEPPER HAMILTON LLP  
500 Grant Street, 50<sup>th</sup> Floor  
Pittsburgh, PA 15219  
Tel: 610.640.7855  
Fax: 610.640.7835



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substantive form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

### Complete if Known

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,780,220	07-14-1998	Weiner et al.	
	2	US-6,039,968	03-21-2000	Nabahi	
	3	US-4,296,206	10-20-1981	Simons	
	4	US-4,386,085	05-31-1983	Teutsch	
	5	US-4,447,424	05-08-1984	Teutsch	
	6	US-4,477,445	10-16-1984	Philibert	
	7	US-4,519,946	05-28-1985	Teutsch	
	8	US-4,540,686	09-10-1985	Philibert	
	9	US-4,547,493	10-15-1985	Teutsch	
	10	US-4,634,695	01-06-1987	Torelli	
	11	US-4,634,696	01-06-1987	Teutsch	
	12	US-4,753,932	06-28-1988	Teutsch	
	13	US-4,774,236	09-27-1988	Cook	
	14	US-4,814,327	03-21-1989	Ottow	
	15	US-4,829,060	05-09-1989	Ottow	
	16	US-4,861,763	08-29-1989	Cook	
	17	US-4,912,097	03-27-1990	Teutsch	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	18	GB 929271	06-19-1963	Philips		
	19	WO 92/19616	11-12-1992	Guerrini		
	20	JP 62012791	01-21-1987	Osaka Chem Lab		
	21	WO 01/01996	01-11-2001	University Of Western Australia		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	22	US-5,223,261	06-29-1993	Nelson	
	23	US-5,380,760	01-10-1995	Wendel	
	24	US-5,702,720	12-30-1997	Effing	
	25	US-6,132,760	10-17-2000	Hedenstrom	
	26	US-3,832,252	10-02-1972	Higuchi, et al.	
	27	US-3,854,480	06-02-1970	Zaffaroni	
	28	US-4,957,119	09-18-1990	De Nijs	
	29	US-5,756,115	05-26-1998	Moo-Young	
	30	US-3,845,770	06-05-1972	Theeuwes, et al.	
	31	US-3,916,899	02-07-1976	Theeuwes, et al.	
	32	US-4,008,719	02-02-1976	Theeuwes, et al.	
	33	US-4,014,334	02-02-1976	Theeuwes, et al.	
	34	US-4,058,122	12-15-1976	Theeuwes, et al.	
	35	US-4,116,241	12-15-1976	Theeuwes, et al.	
	36	US-4,160,452	04-07-1977	Theeuwes	
	37	US-3,173,876	05-27-1960	Zobrist	
	38	US-3,276,586	10-04-1966	Rosaen	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	39	US-3,541,005	02-05-1969	Strathmann, et al.	
	40	US-3,541,006	07-03-1968	Bixler, et al.	
	41	US-3,546,876	10-18-1968	Fokker, et al.	
	42	US-3,133,132	11-29-1960	Loeb, et al.	
	43	US-4,160,020	07-03-1979	Ayer	
	44	US-4,943,566	07-24-1990	Nedelec	
	45	US-4,490,954	01-01-1985	Cresti	
	46	US-4,978,657	12-18-1990	Teutsch	
	47	US-5,006,518	04-09-1991	Moguilewsky	
	48	US-5,043,332	08-27-1991	Teutsch	
	49	US-5,064,822	11-12-1991	Philibert	
	50	US-5,073,548	12-17-1991	Cook	
	51	US-5,089,488	02-18-1992	Ottow	
	52	US-5,089,635	02-18-1992	Neef	
	53	US-5,093,507	03-03-1992	Scheidges	
	54	US-5,095,010	03-10-1992	Elger	
	55	US-5,095,129	03-10-1992	Ottow	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449A/PTO

***(Use as many sheets as necessary)***

Sheet	4	of	9
-------	---	----	---

<i>Application Number</i>	10/561,656
<i>Filing Date</i>	Herewith
<i>First Named Inventor</i>	Jong Joseph Kim
<i>Art Unit</i>	1617
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	133121.00201

[illegible][illegible]

Date Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	61	Agarwal et al., "Glucocorticoid Antagonists," <i>FEBS Letters</i> (1987) 217:221-226.	
	62	Ali et al., "Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation," <i>J. Virol</i> (1995) 69:6367-6375	
	63	Ali et al., "The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation," <i>Proc. Nat'l Acad. Sci. USA</i> (1997) 94:2249-2254	
	64	Asano et al., "Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA binding and macromolecular assembly," <i>J. Biol. Chem.</i> (1997) 272: 27042-27052	
	65	Ayyavoo et al., "HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B," <i>Nat Med.</i> (1997) 3:1117-23	
	66	Ayyavoo et al., "HIV-1 viral protein R compromises cellular immune function in vivo," <i>Int Immunol</i> (2002) 14: 13-22	
	67	Bamberger et al., "Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids," <i>Endocr Rev</i> (1996) 17: 245-261	
	68	Beato et al., "Interaction of steroid hormone receptors with the transcription initiation complex," <i>Endocr Rev.</i> (1996) 17: 587-609	
	69	Blackwell et al., "Translation elongation factor-1 alpha interacts with the 3' stem-loop region of West Nile Virus genomic RNA," <i>J. Virol</i> (2000) 71:6433-6444	
	70	Blight et al., "Efficient initiation of HCV RNA replication in cell culture," <i>Sci</i> (2000) 290:1972	
	71	Brown et al., "Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNA's," <i>Nucleic Acids Res</i> (1992) 20:5041-5045	
	72	Buratti et al., "Functional analysis of the interaction between HCV 5' UTR and putative subunits of eukaryotic initiation factor eIF3," <i>Nucleic Acids Res</i> (1998) 26:3179-3187	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	73	Chrousos "The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation," <i>N. Engl. J. Med.</i> (1995) 332:1351-1362	
	74	Croxatto et al., "Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle," <i>Human Reprod.</i> (1992) 7:945-50	
	75	Fletcher et al., "Pestivirus internal ribosome entry site (IRES) structure and function: Elements in the 5' untranslated region important for IRES function," <i>J Virol</i> (2002) 76:5024-5033	
	76	Fukushi et al., "Specific interaction of a 25-kilodalton cellular protein, a 40S ribosomal subunit protein with the internal ribosome entry site of hepatitis C virus genome," <i>Virus Genes</i> (1999) 19:153-161	
	77	Hahm et al., "Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus," <i>Journal of Virology</i> (1998) 72:8782-8788	
	78	Honda et al., "Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA," <i>RNA</i> (1996a) 2:955-968	
	79	Honda et al., "Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA," <i>Virology</i> (1996b) 222:31-42	
	80	Honda et al., "A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation," <i>J. Virol</i> (1999) 73:1165-1174	
	81	Htun et al., "Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera," <i>Proc. Nat'l Acad. Sci. U.S.A.</i> (1996) 93:4845-4850	
	82	Jang et al., "A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation," <i>J. Virol</i> (1988) 62:2636-2643	
	83	Jang et al., "Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes," <i>Biochem Pharmacol</i> (1996) 52:753-761.	
	84	Kieft et al., "Mechanism of ribosome recruitment by hepatitis C IRES RNA," <i>RNA</i> (2001) 7(2):194-206.	
	85	Kieft et al., "The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold," <i>J. Mol. Biol.</i> (1999) 292:513-529	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	86	Kino et al., "The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor," <i>J. Exp. Med.</i> (1999) 189: 51-62	
	87	Korba et al., "Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication," <i>Antivir. Res.</i> (1992) 19:55.	
	88	Le et al., "Unusual folded regions and ribosome landing pad within hepatitis C virus and pestivirus RNA's," <i>Genes</i> (1995) 154:137-143	
	89	Mahalingam et al., "HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle," <i>Proc. Nat'l Acad. Sci. U.S.A.</i> (1998) 98: 3419-3424	
	90	Malancha et al., "Mov34 protein from mouse brain interacts with the 3' noncoding region of Japanese encephalitis virus," <i>J. Virol</i> (2000)74:5108-5115	
	91	McNally et al., "The glucocorticoid receptor: rapid exchange with regulatory sites in living cells," <i>Science</i> (2000) 287:1262-1265	
	92	Merrick et al., "The pathway and mechanism of eukaryotic protein synthesis," <i>Translational Control</i> (1996) 33-69	
	93	O'Connor et al., "Downstream ribosomal entry for translation of coronavirus TGEV gene 3b," <i>Virology</i> (2000) 269:172-82	
	94	Pain, "Initiation of protein synthesis in eukaryotic cells," <i>Eur J. Biochem.</i> (1996) 236:747-771	
	95	Pelletier et al., "Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA," <i>Nature</i> (1988) 334:320-325	
	96	Pestova et al., "Aprokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNA's," <i>Genes &amp; Dev.</i> (1998) 12:67-83	
	97	Pickering et al., "Predicted secondary structure of the hepatitis G virus and GB virus-A 5' untranslated regions consistent with an internal ribosome entry site," <i>J. Viral Hepat</i> (1997) 4:175-184	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	98	Psaridi et al., "Mutational analysis of a conserved tetraloop in the 5' untranslated region of hepatitis C virus identifies a novel RNA element essential for the internal ribosome entry site function," <i>FEBS Lett</i> (1999) 453:49-53	
	99	Raman et al., "Stem-loop III in the 5' untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication," <i>J. Virol</i> (2003) 77:6720-30	
	100	Reilly et al., "Mechanism-based inhibition of rat liver microsomal diazepam C <sub>3</sub> -hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450," <i>Chemico-Biological Interactions</i> (1999) 118:39-49	
	101	Rijnbrand et al., "Internal ribosome entry site-mediated translation in hepatitis C virus replication," <i>Curr. Top Microbiol. Immunol.</i> (2000) 242:85-116	
	102	Rijnbrand et al., "Almost the entire 5' non-translated region of hepatitis C virus is required for cap-independent translation," <i>FEBS Lett</i> (1995) 365:115-119	
	103	Sachs et al., "Starting at the beginning, middle, and the end: translation initiation in eukaryotes," <i>Cell</i> , (1997) 89:831-838	
	104	Sarkar "Mifepristone: bioavailability, pharmacokinetics and use-effectiveness," <i>Eur J of Obstetrics &amp; Gynecol and Reprod. Biol.</i> (2002) 101:113-120.	
	105	Sherman et al., "Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest," <i>J. Virol</i> (2000) 74:8159-8165	
	106	Shibata et al., "Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action," <i>Recent Prog. Horm. Res.</i> (1997) 52:141-164	
	107	Sizova et al., "Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNA's," <i>J. Virol</i> (1998) 72:4775-4782	
	108	Swahn et al., "Plasma levels of anti-progestin Ru486 following oral administration to non-pregnant and early pregnant women," <i>Contraception</i> 34 (1986) pp. 469-481	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 9 of 9

**Complete if Known**

Application Number	10/561,656
Filing Date	Herewith
First Named Inventor	Jong Joseph Kim
Art Unit	1617
Examiner Name	To Be Determined
Attorney Docket Number	133121.00201

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	109	Tang et al., "Alterations to both the primary and predicted secondary structure of stem-loop IIIc of the hepatitis C virus 1b 5' untranslated region (5'UTR) lead to mutants severely defective in translation which cannot be complemented in trans by the wild-type 5'UTR sequence," <i>J. Virol</i> (1999) 73:2359-2364	
	110	Varaklioti et al., "Mutational analysis of two un-structured domains of the 5' untranslated region of HCV RNA," <i>Biochem. Biophys. Res. Commun.</i> (1998) 253:678-685	
	111	Wang et al., "A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA," <i>J. Virol</i> (1994) 68:7301-7307.	
	112	Wang et al., "An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' uncoding region," <i>RNA</i> (1995) 1:526:537-542.	
	113	Yen et al., "Cellular proteins specifically bind to the 5'-noncoding region of hepatitis C virus RNA," <i>Virology</i> (1995) 208:723-732	
	114	Scott et al., <i>Handbook of Common Polymers</i> , CRC Press, Cleveland, OH (1971).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.